Core Points - Zentek Ltd. has announced an increase in its non-brokered private placement to a total of up to $2,500,000, allowing for the issuance of up to 2,358,490 Units at a price of $1.06 per Unit [1] - The proceeds from the Offering will be utilized for working capital and general corporate purposes [1] Summary by Sections Offering Details - Each Unit consists of one Common Share, one-half of a Series A Warrant, and one-half of a Series B Warrant [2] - Series A Warrants allow the purchase of one Common Share at $1.50 for 24 months, with potential acceleration if the share price reaches $2.00 for 10 consecutive trading days [3] - Series B Warrants allow the purchase of one Common Share at $2.00 for 36 months, with potential acceleration if the share price reaches $3.00 for 10 consecutive trading days [4] Regulatory and Compliance - The closing of the Offering is subject to necessary corporate and regulatory approvals, including TSXV approval [5] - All securities issued will be subject to a hold period of four months plus a day from the date of issuance [5] Company Overview - Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of innovative products [7] - The company's patented technology platform, ZenGUARD™, enhances viral filtration efficiency for surgical masks and HVAC systems [8] - Zentek holds a global exclusive license to an Aptamer-based platform technology developed by McMaster University for diagnostic and therapeutic markets [10]

Core Viewpoint - Zentek Ltd. announces a non-brokered private placement to raise up to $2,000,000 through the issuance of units priced at $1.06 each, aimed at funding working capital and general corporate purposes [1]. Group 1: Private Placement Details - The offering will consist of up to 1,886,792 units, each unit comprising one common share, one-half of a Series A warrant, and one-half of a Series B warrant [2]. - Series A warrants allow the purchase of one common share at $1.50 for 24 months, with potential acceleration if the share price exceeds $2.00 for 10 consecutive trading days [3]. - Series B warrants permit the purchase of one common share at $2.00 for 36 months, with acceleration possible if the share price exceeds $3.00 for 10 consecutive trading days [4]. Group 2: Regulatory and Approval Information - The closing of the offering is contingent upon receiving necessary corporate and regulatory approvals, including from the TSX Venture Exchange [5]. - All securities issued will be subject to a four-month hold period from the date of issuance [5]. Group 3: Stock Options and Restricted Share Units - The company has granted stock options to certain officers, directors, and employees to acquire a total of 979,000 common shares at $1.06 per share, with a vesting schedule over five years [7]. - Additionally, 779,000 restricted share units have been granted, vesting on October 1, 2026 [7]. Group 4: Company Overview - Zentek is an intellectual property development and commercialization company focused on creating novel products that enhance the safety and efficiency of commercial partners' offerings [8][9]. - The company holds a global exclusive license for an Aptamer-based platform technology developed by McMaster University, targeting diagnostic and therapeutic markets [10].

Core Points - Zentek Ltd. is updating its slate of director nominees for the upcoming annual general and special meeting scheduled for September 25, 2025 [1] Company Updates - The announcement follows a previous news release dated September 3, 2025, indicating ongoing developments within the company [1]

Core Viewpoint - Zentek Ltd. has successfully closed a non-brokered private placement of debenture units, raising gross proceeds of $2,000,000 through the issuance of 2,000 debenture units [1] Group 1: Offering Details - Each debenture unit consists of $1,000 principal amount of 5% secured convertible debentures and 454 warrants to purchase common shares [2] - The convertible debentures will mature on April 9, 2028, and bear interest at a rate of 5% per annum, payable as a balloon payment on the maturity date [2] - The conversion price for the convertible debentures is set at $2.20 per common share, with the company having the option to force conversion if the trading price exceeds $4.40 [2] Group 2: Security and Warrants - The convertible debentures are secured by the company's interest in 521 mining claims held by its subsidiary Albany Graphite Corp., with a first ranking above all other creditors [3] - A total of 908,000 warrants were issued, each allowing the holder to purchase one common share at the conversion price until the maturity date [4] - The warrants will vest only upon the completion of a sale or transfer of the secured assets to a third party [4] Group 3: Use of Proceeds and Regulatory Approval - Net proceeds from the offering will be utilized for working capital and general corporate purposes [5] - The closing of the offering is subject to necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [5] Group 4: Company Overview - Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of novel products [7] - The company's patented technology platform, ZenGUARD™, significantly increases bacterial and viral filtration efficiency for surgical masks and aims to enhance HVAC systems [9]